Corbus Pharmaceuticals Holdings

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its products include candidate, Lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded in April 2009 and is headquartered in Norwood, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.

A licensing agreement enabled the clinical-stage biotech to report a big jump in revenue and a nice profit in Q2.

What You'll Want to Know About Corbus Pharmaceuticals' Q2 Results

Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of 113.64% and 181.93%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Corbus Pharmaceuticals (CRBP) Q2 Earnings and Revenues Beat Estimates

GW Pharmaceuticals

New Age Beverages

Tilray Brands

Zynerba Pharmaceuticals

The bottom line: a whole lot of uncertainty.

Here's What Last Week's FDA CBD Hearing Really Means for Cannabis Stocks

Here's what investors need to know about this company's synthetic cannabinoid.

Is Corbus Pharmaceuticals a Buy Now?

The clinical-stage biotech's top- and bottom-line numbers weren't the most important thing in the first quarter.

What You Need to Know About Corbus Pharmaceuticals' Q1 Earnings Update

Corbus Pharmaceuticals Holdings, Inc. (CRBP) CEO Yuval Cohen on Q1 2019 Results - Earnings Call Transcript

Corbus (CRBP) will provide updates on its lead candidate lenabasum, when it releases first-quarter 2019 results.

What's in the Cards for Corbus (CRBP) This Earnings Season?

Corbus Pharmaceuticals (CRBP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Corbus Pharmaceuticals (CRBP) to Report Q1 Results: Wall Street Expects Earnings Growth

Corbus recently announced that it had changed the primary clinical endpoint for the Phase 3 study of lenabasum in systemic sclerosis based on feedback from the FDA.

Corbus And Lenabasum In Systemic Sclerosis: The Primary Endpoint Update

Corbus Pharmaceuticals (CRBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Corbus Pharmaceuticals Rating Upgrade to Buy

An analyst's favorable opinion of the biotech stock stirred up investors' excitement.

Why Corbus Pharmaceuticals Soared Today

Which stock wins in a matchup between these two cannabinoid-focused biotechs?

Better Buy: GW Pharmaceuticals (GWPH) vs. Corbus Pharmaceuticals (CRBP)

Corbus Pharmaceuticals (CRBP) closed the most recent trading day at $7.23, moving -1.23% from the previous trading session.

Corbus Pharmaceuticals (CRBP) Stock Moves -1.23%: What You Should Know

Corbus Pharmaceuticals (CRBP) closed at $7.18 in the latest trading session, marking a -0.97% move from the prior day.

Corbus Pharmaceuticals (CRBP) Stock Sinks As Market Gains: What You Should Know

A presentation reminded investors of the potential in the biotech's endocannabinoid candidates.

Here's Why Corbus Pharmaceuticals Is on the Move Today

CRBP earnings call for the period ending December 31, 2018.

Corbus Pharmaceuticals Holdings Inc (CRBP) Q4 2018 Earnings Conference Call Transcript

Corbus Pharmaceuticals delivered earnings and revenue surprises of -36.36% and -3.02%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

Corbus Pharmaceuticals (CRBP) Reports Q4 Loss, Misses Revenue Estimates

News for Corbus Pharmaceuticals Holdings Stock (CRBP)